1 In this study, we examined the mechanism(s) by which s.c. nicotine inhibits synovial plasma extravasation. We found that nicotine dose-dependently inhibited bradykinin (BK)-and platelet activating factor (PAF)-induced plasma extravasation. 2 The eect of nicotine on both BK-and PAF-induced plasma extravasation was attenuated by adrenal medullectomy. ICI-118,551 (a selective b 2 -adrenoceptor blocker) (30 mg ml
Introduction
It has been shown that nicotine activates primary aerent nociceptors (Steen & Reeh, 1993) and that nicotinic cholinergic circuitry plays a role in nociceptive pathways (e.g., Rogers & Iwamoto, 1993; Khan et al., 1994) . Since pain is a component of the in¯ammatory process (dolore) and since activation of primary nociceptors also attenuates microvascular permeability (Green et al., 1995, and unpublished observation) , via neural and endocrine circuits (Green et al., 1995) , we hypothesized that activating nociceptive pathways, through stimulation of the nicotinic cholinergic circuitry may also suppress synovial plasma extravasation and that such an action is mediated by the same neural/endocrine circuit.
Recently, we found that nicotine (s.c.), starting at doses as low as 0.01 mg kg 71 , inhibited the plasma extravasation induced by the in¯ammatory mediator, bradykinin (BK) (Miao et al., 1992a) , in part via an adrenal medulla-dependent mechanism (Miao et al., 1992a,b) . The factors mediating this inhibitory action have not been clari®ed. Since nicotine can release adrenaline from the adrenal medulla (Cryer et al., 1976; McKay & Trent-Sanchez, 1990 ) and since activation of b 2 -adrenoceptors in the knee joint, by salbutamol, inhibits BKinduced plasma extravasation (Coderre et al., 1990; 1991) , it has been suggested that the inhibitory action of nicotine on BK-induced plasma extravasation is mediated by adrenaline (Miao et al., 1992a,b) . However, no increase in plasma adrenaline was detected following administration of nicotine at doses below 1 mg kg 71 , s.c. by use of a very sensitive high performance liquid chromatographic (h.p.l.c.) assay (unpublished data). Since b 2 -adrenoceptors occur presynaptically on sympathetic postganglionic neurone terminals, we compared the eect of nicotine on the sympathetic postganglionic neurone terminal-dependent plasma extravasation induced by a relatively low dose of BK (Miao et al., 1996a,b) with that induced by platelet activating factor (PAF), an in¯ammatory mediator that stimulates plasma extravasation independently of sympathetic mechanisms (Green et al., 1993a; Miao et al., 1996a,b) .
In addition to adrenaline, other adrenal medullary hormones (e.g., enkephalins and neuropeptide Y) which can be released by nicotine (Hexum & Rusett, 1989; Stachowiak et al., 1990; Wilson, 1991) also inhibit synovial plasma extravasation (Green et al., 1993b) . Finally, corticosterone, an adrenal cortical hormone, can be released by nicotine (Pomerleau & Pomerleau, 1990; Donnerer & Lembeck, 1990; Krueger et al., 1991; Stalke et al., 1992) . Although its action on synovial plasma extravasation is not known, glucocorticoid inhibits plasma extravasation in many tissues (Tsurufuji et al., 1980; Seghaye et al., 1986; Brattsand et al., 1991) . Therefore, we tested the hypothesis that these adrenal hormones also contribute to the inhibitory eect of nicotine.
Finally, since nicotine can release glucocorticoids via an action on the central nervous system (Krueger et al., 1991; Matta et al., 1990; and as spinal pathways mediate part of the inhibitory eect of nicotine on synovial plasma extravasation (Miao et al., 1994) , we also studied the role of spinal nicotinic receptors.
Methods
The experiments were performed on male Sprague-Dawley rats (300 ± 400 g, from Bantin and Kingman, Fremont, CA) that were anaesthetized with sodium pentobarbitone (50 mg kg 71 , i.p.) (Anthony Products Co., Arcadia, CA).
Perfusion of the knee joint
Knee joint perfusion was performed, as previously described (Coderre et al., 1989) . In brief, after incision of the skin and connective tissue overlying the anterior aspect of the knee, Evans blue dye (50 mg kg 71 ) was administered i.v. in the saphenous vein via a 30-gauge hypodermic needle which was then withdrawn from the vein. Ten minutes after injection of the dye, a 30-gauge needle was inserted into the cavity of the knee joint for the infusion of¯uid (250 ml min
71
, controlled by a syringe pump from Sage Instruments, Model 351, Cambridge, MA). After infusion of an initial volume of 100 ± 200 ml of vehicle, a second needle (25-gauge) was inserted into the knee joint, approximately 3 mm from the in¯ow needle. This second needle served as an out¯ow cannula. Fluid was withdrawn from the joint through the out¯ow cannula by a second syringe pump. The perfusing¯uid was infused and withdrawn at a constant rate of 250 ml min 71 . Perfusate samples were collected every 5 min for a period of 85 min. Samples were analysed for the amount of Evans blue dye by spectrophotometric measurement of absorbance at 620 nm. The absorbance at this wavelength is linearly related to dye concentration (Carr & Wilhelm, 1964) .
After a baseline perfusion period of 15 min with vehicle (normal saline), plasma extravasation into the knee joint was stimulated by adding BK (160 ng ml 71 or approximately 0.15 mM) or PAF (52.4 ng ml 71 or 0.1 mM) to the perfusion uid. These doses of BK and PAF have previously been demonstrated to be ED 50 values on their respective dose-response curves (Green et al., 1993a) . Of note, the concentration of BK in various in¯amed tissues is in the range of 50 nM to 0.1 mM Hargreaves et al., 1993 and Hargreaves, personal communication) while that of PAF is approximately 1.7 mM Appleyard & Hillier, 1995) . A similar concentration of BK has been used as a component of socalled`in¯ammatory soup' (e.g., Steen et al., 1995) . Experiments involving both knee joints in the same rat were performed simultaneously.
Drug administration protocols
Nicotine To evaluate the eect of nicotine on synovial plasma extravasation induced by BK and PAF, we administered nicotine s.c. in the neck. Nicotine was prepared in 0.1 ml normal saline. Two doses of nicotine were administered in individual groups of animals (0.01 mg kg 71 and 1 mg kg
71
). Since the inhibitory eects of these doses were similar to those produced in a cumulative dose-response curve (data not shown), they were selected to allow examinion of the mechanism of action of nicotine at dierent doses. Since the eect of a mid-dose (3 mg kg 71 ) of nicotine (data not shown) was similar to that induced by low-dose nicotine, only the eect of the latter dose is presented. Synovial plasma extravasation was sampled every 5 min (starting 30 min before administration of nicotine until 40 min after injection of nicotine). The time interval between nicotine injection and the maximum inhibition of plasma extravasation by nicotine was 30 min (Miao et al., 1992a) .
ICI-118,551
To study the contribution of adrenaline to the nicotinic inhibition of BK-or PAF-induced plasma extravasation, we co-perfused ICI-118,551 (erythro-(I)-I-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol hydrochloride), a selective b 2 -adrenoceptor antagonist, into the knee joint at a concentration of 30 mg ml
71
. Although ICI-118,551 has not been examined for cross-binding with the nicotinic receptor, the speci®city for this drug has been demonstrated by pharmacological (Chojnacka-Wojcik & Przegalinski, 1991; Veltmar et al., 1992) as well as receptor binding approaches (Bjornerheim et al., 1991; Pauwels et al., 1991) . The dose we used in this experiment was taken from studies which showed that ICI-118,551 is eective in antagonizing the inhibition of BK-induced plasma extravasation by salbutamol (a selective b 2 -adrenoceptor agonist) (Coderre et al., 1990; 1991) . ICI-118,551 was injected intra-articularly so as to achieve minimum systemic action. To demonstrate this and to identify its site of action one knee was perfused with ICI-118,551 and BK and the contralateral knee, as a control, received BK alone.
Naloxone We administered naloxone, an opioid receptor antagonist, to explore the contribution of endogenous opioids to inhibition of plasma extravasation by s.c. nicotine. Naloxone was given 30 min before the beginning of the experiments (two hourly injections of 1 mg kg 71 , i.p.). This dose of naloxone has been used previously and shown to be eective in antagonizing the eects of opioid receptor agonists (Taguchi et al., 1993) .
RU-38,486 (mifepristone) To examine the contribution of glucocorticoids to nicotine-induced inhibition of BK-or PAFinduced plasma extravasation, we pretreated some rats, 3 h before the commencement of the knee joint perfusion, with RU-38,486 (30 mg kg 71 , s.c.), a glucocorticoid and progesterone receptor antagonist. A similar protocol with RU-38,486 at this dose has been found to be eective in antagonizing actions mediated by glucocorticoid receptors in other systems (Peeters et al., 1992) .
Metyrapone Since RU-38,486 inhibits both glucocorticoid and progesterone receptors (Philibert et al., 1989) , we also studied groups of rats treated with metyrapone (two hourly injections of 100 mg kg 71 , i.p.), a substance which blocks glucocorticoid synthesis (MacNiven & de Catanzaro, 1990) with no inhibitory actions on progesterone-mediated eects (Rondinone et al., 1992) . Metyrapone is believed to deplete glucocorticoids rapidly by inhibiting the conversion of 11-deoxy-corticosterone to corticosterone (Herman et al., 1992) . This protocol of metyrapone administration has been found to be eective in inhibiting adrenal corticosteroid synthesis (Jacobson et al., 1989; Philibert et al., 1989; Herman et al., 1992; Green et al., 1995) .
Mecamylamine To examine if spinal nicotinic receptors are activated by s.c. nicotine, we administered mecamylamine spinally. The dose of mecamylamine used in the present intrathecal protocol (0.025 mg kg 71 ) has been found to be ineective, when given i.v., in aecting s.c. nicotine inhibition of BK-induced plasma extravasation (Miao et al., 1994) .
Mecamylamine was injected into the lumbar section of the spinal cord via a PE 10 catheter (i. Since i.t. mecamylamine (equivalent to 0.167 mg kg
, a dose approximately 7 times higher than the one we used in the present study) reverses i.t. nicotine (equivalent to 1.42 ± 1.67 mg kg 71 )-induced hypertension (from normal blood pressure of 100 ± 110 mmHg to 145 ± 155 mmHg) (Khan et al., 1994) , we conducted experiments to examine if i.t. mecamylamine 0.025 mg kg 71 aects systemic blood pressure. In order to conduct a paired comparison for the action of i.t. mecamylamine, BK-induced plasma extravasation and systemic blood pressure were simultaneously measured over 5 min intervals. First intrathecal normal saline was administered, after the level of BK-induced plasma extravasation and systemic blood pressure were stable. Mecamylamine (0.025 mg kg 71 ) at the same volume (10 ml) was injected 15 min after i.t. normal saline (10 ml). In these experiments, we found that neither BKinduced plasma extravasation nor systemic blood pressure was aected by i.t. normal saline (BK-induced plasma extravasation: 0.106+0.11 vs. 0.112+0.14 absorbance at 620 nm, n=8; systemic blood pressure: 94+7 vs. 89+5 mmHg, n=4, both P40.05, Student's t test; representing 5.66% increase in plasma extravasation and 4.84% decrease in blood pressure) or by i.t. mecamylamine (BK-induced plasma extravasation: 0.106+0.11 vs. 0.110+0.14 absorbance at 620 nm, n=8; systemic blood pressure: 94+7 vs. 92+5 mmHg, n=4, both P40.05; representing 3.77% increase in plasma extravasation and 2.61% decrease in blood pressure).
Combination of ICI-118,551, RU-38,486 and naloxone To examine if there is more than one mechanism which mediates the action of nicotine, we used combined administration of agents that act through the three proposed pathways. In this experiment, RU-38,486 was administered (30 mg kg 71 , s.c.) 3 h before the knee joint perfusion was started, naloxone (two hourly injections of 1 mg kg 71 , i.p.) was given 30 min before the start of the knee joint perfusion and ICI-118,551 (30 mg ml 71 ) was co-perfused with BK (160 ng ml 71 ) intraarticularly into the knee joint.
Surgical procedures
Adrenal medullectomy To assess the contribution of the adrenal medulla to the eects of nicotine on plasma extravasation we performed bilateral surgical adrenal medullectomy, as previously described (Wilkinson et al., 1981; Miao et al., 1993) . Under ether anaesthesia, the adrenal gland was located through an incision in the lateral abdominal wall, an incision made in the adrenal gland and the adrenal medulla enucleated. Rats were given 0.5% saline, in place of water, to drink for the ®rst 7 days after surgery (Wilkinson et al,. 1981) . Since incising the adrenal gland causes trauma to the adrenal cortex, adrenal medullectomy was performed at least 5 weeks before the knee joint perfusion experiments to allow recovery of function of the adrenal cortex; but the stress-induced increase of plasma corticosterone is still somewhat lower than in normal rats at this time (Wilkinson et al., 1981) . The magnitudes of the response of BK and PAF-induced plasma extravasation in the dierent experimental groups were, with some exceptions (see Table 1 ), not signi®cantly dierent.
Statistics
Data are presented as mean+s.e.mean. The plateau levels of BK-or PAF-induced plasma extravasation, before injection of nicotine, served as control values. The maximum decrease of BK-or PAF-induced plasma extravasation over a period of 45 min after injection of nicotine was recorded and converted into percentage change from the control plateau value obtained before administration of nicotine (i.e., magnitude of inhibition by nicotine) (Miao et al., 1992b) . Signi®cant dierences between maximum inhibition for pairs of groups of rats, produced after s.c., injection of nicotine, were determined by unpaired Student's t test. Dierences were considered statistically signi®cant at a P value 50.05.
Materials
The drugs used in the present experiments were: bradykinin acetate, platelet activating factor (PAF, L-a-phosphatidylcholine, b-acetl-g-o-hexadecyl), bovine serum albumin (BSA), mecamylamine hydrochloride, nicotine hydrogen tartrate, naloxone hydrochloride, dimethyl sulphoxide (DMSO), and peanut oil from Sigma Chemical Co., St. Louis, MO; ICI-118, 551 [erythro-(+)-I(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol hydrochloride] from Cambridge Research Biochemicals Incorporated (Gadbrook Park Northwich, Cheshire, U.K.). RU-38,486 (mifepristone) and metyrapone (metopirone) were generous gifts from Roussel Uclaf, France and Ciba-Geigy Pharmaceutical Co., Ardsley, NY, respectively. PAF was dissolved in freshly prepared 0.25% BSA in normal saline solution. ICI-118,551 was initially dissolved in 100% ethanol in trace volume, and further diluted with normal saline (®nal concentration of ethanol 50.05%). RU-38,486 was suspended in peanut oil. Metyrapone was dissolved in DMSO. The remaining compounds were dissolved in normal saline.
Results

Eects of nicotine (s.c.) on BK-and PAF-induced plasma extravasation
Nicotine (s.c.) inhibited BK-and PAF-induced plasma extravasation (Figures 1 ± 4) . The dose-response relationship produced by nicotine given by the cumulative dosing regimen was similar to that obtained from experiments with nicotine at low, mid, and high doses, based on the non-cumulative dosing regimen (data not shown). Results from non-cumulative dosing regimen 
Eects of surgical and pharmacological interventions on actions of nicotine
Eect of adrenal medullectomy To examine the contribution of the adrenal medulla, we studied the eect of adrenal medullectomy on actions produced by nicotine. Inhibition of BKor PAF-induced plasma extravasation by nicotine at low (0.01 mg kg 71 ) and high (1 mg kg 71 ) doses was signi®cantly attenuated by bilateral adrenal medullectomy (all P50.01) (Figure 1a and b and Table 1 ).
Eect of intra-articularly administered b 2 -adrenoceptor antagonist To determine if adrenaline, an adrenal medullary b 2 -adrenoceptor agonist released by nicotine, mediates the decrease of BK-induced plasma extravasation, we next examined the eect of blocking local b 2 -adrenoceptors by intra-articular ICI-118,551 (30 mg ml 71 ) on the actions of nicotine. The inhibitory action produced by high-dose nicotine on BK-induced plasma extravasation, was signi®cantly attenuated by ICI-118,551 (P50.01) (Figure 1a and Table 1 ). The eect of lowdose nicotine on BK-induced plasma extravasation and the inhibitory action of both doses of nicotine on PAF-induced plasma extravasation were not signi®cantly aected by ICI-118,551 (P40.05) (Figure 1a and b and Table 1) .
To rule out a contribution of b 2 -adrenoceptors at extraarticular sites, we conducted another experiment in which one knee was perfused with BK and ICI-118,551, while the contralateral knee, serving as a control, was perfused with BK alone. Since only the action produced by high-dose nicotine is mediated by b 2 -adrenoceptors (Figure 1a ), this particular dose was used to test the contribution of systemic action of adrenaline to the nicotine inhibition of BK-induced plasma extravasation. The inhibitory eect of nicotine on BK-induced plasma extravasation was signi®cantly attenuated in knees which received intra-articular ICI-118,551 but was not aected in the contralateral knee (P50.01) (data not shown).
Eect of systemically administered opioid receptor antagonist To evaluate the role of opioids in nicotine inhibition of plasma extravasation, we examined the eect of blocking opioid receptors by naloxone on the action of nicotine. Inhibition of BK-or PAF-induced plasma extravasation by nicotine at both doses was signi®cantly attenuated by systemic naloxone (two hourly injections of 1 mg kg 71 , i.p.) (P50.01) (Figure 1a and b and Table 1 ).
Eects of administration of inhibitors of glucocorticoids Since nicotine also stimulates release of glucocorticoids, a class of potent anti-in¯ammatory agents, we examined a possible contribution of endogenous glucocorticoids to the action of nicotine. High-dose nicotines inhibition of BK-or PAF-induced plasma extravasation was signi®cantly attenuated by RU-38,486 (30 mg kg 71 , s.c.) or by metyrapone (two hourly injections of 100 mg kg 71 , i.p.) (all P<0.01) (Figure 2a and b and Table 1 ). The actions of low-dose nicotine were not aected by these treatments (all P>0.05) (Figure 2a and b and Table 1 ).
Eects of intrathecal mecamylamine
Since nicotine administered s.c. may cross the blood-brain barrier and nicotinic receptors in the spinal cord may be involved in the activation of the hypothalamo-pituitary-adrenal axis (Krueger et al., 1991) , we also examined eects of blocking the spinal nicotinic receptors on the action of individual doses of nicotine. Inhibition of BK-or PAF-induced plasma extravasation produced by high-dose, but not low-dose, nicotine was signi®cantly attenuated by i.t. mecamylamine (0.025 mg kg 71 ) (both P50.01) (Figure 3a and b and Table 1 ).
Eects of the combination of ICI-118,551, RU-38,486 and naloxone Since the inhibitory action of nicotine may be mediated by one common mechanism or by multiple independent mechanisms, we examined the eects of the combined administration of agents that act through the three proposed pathways, on high-and low-dose nicotine inhibition of BK-induced plasma extravasation. In the combined treatment group, we used RU- In adrenal medullectomized rats, nicotine inhibition of BK-induced was attenuated (cross-hatched columns, n=8). ICI-118,551 did not aect actions produced by low-dose nicotine but attenuated that of high-dose nicotine (hatched columns, n=8). Naloxone attenuated the actions of nicotine (solid columns, n=8). (b) Nicotine also inhibited PAF-induced plasma extravasation in normal rats (open columns, n=8), which was attenuated by adrenal medullectomy (cross-hatched columns, n=8) but not aected by 551 (hatched columns, n=8) . Naloxone attenuated the actions of nicotine (solid columns, n=8). *Signi®cantly dierent from the action produced by the same dose of nicotine in control rats. , intra-articularly) to block the pathways mediated by glucocorticoids, opioids and adrenaline, respectively. Compared with the eect of individual antagonists, the attenuation of low-dose nicotine inhibition was not signi®cantly dierent from that of the combined treatment (P40.05) (Figure 4) . However, the attenuation of high-dose nicotine was signi®cantly greater in the combined treatment group when it was compared with the eects of individual antagonist (P50.05) (Figure 4 ).
Discussion
In this study we con®rm our previous ®nding that s.c. nicotine inhibits BK-induced synovial plasma extravasation (Miao et al., 1992a) and extend these studies to determine the underlying mechanisms. We found that nicotine inhibits BK-or PAF-induced plasma extravasation, which was partially attenuated by adrenal medullectomy. However, ICI-118,551, an antagonist blocking the major receptors for adrenaline (a key adrenal medullary hormone), only attenuated the inhibitory actions of high-dose nicotine on BK-, but not PAF-, induced plasma extravasation without aecting those of low-dose nicotine. Therefore, adrenaline is unlikely to mediate all the adrenal medulla-dependent actions of nicotine. Since the adrenal medulla also releases opioids upon stimulation by nicotine (Wilson, 1991) , which can block synovial plasma extravasation as well (Green & Levine, 1992) , we used an opioid receptor antagonist to examine their contribution to the inhibitory action of nicotine. Our ®ndings suggest that opioids contribute to the inhibitory eects of all doses of nicotine. The contribution of neuropeptide Y (NPY), another adrenal medullary hormone released by nicotine (Hexum & Rusett, 1989) that can block synovial plasma extravasation (Green et al., 1993b) , was not examined because of the lack of an eective receptor antagonist.
The observation that ICI-118,551 treatment in one knee did not aect the action of nicotine in the contralateral knee suggests that local b 2 -adrenoceptors in the joint mediate the inhibitory action of nicotine. The b 2 -adrenoceptor-mediated eect of nicotine aected only plasma extravasation induced by BK, which is dependent on sympathetic postganglionic neurone terminals in the joint at the dose used in the present study (Coderre et al., 1989; Miao et al,. 1996a,b) , but not that induced by PAF, an in¯ammatory mediator which is independent of nerve innervation (Green et al., 1993a) . This ®nding further indicates that the sympathetic postganglionic neurone terminal in the joint is the site at which b 2 -adrenoceptor agonists act to inhibit plasma extravasation.
In addition to adrenal medullary hormones, we also explored the role of adrenal cortical hormones in mediating the inhibitory action of nicotine because they can be released by nicotine (Pomerleau & Pomerleau, 1990; Donnerer & Lembeck, 1990; Krueger et al., 1991) and inhibit plasma extravasation in extra-articular tissues (Tsurufuji et al., 1980; Seghaye et al., 1986; Brattsand et al., 1991) . At a dose of 1 mg kg 71 (a dose similar to those previously found to release glucocorticoids, i.e., 0.25 mg kg 71 in Donnerer & Lembeck, 1990 and 4.5 mg kg 71 in Krueger et al., 1991) , nicotine inhibition of BK-and PAF-induced plasma extravasation was attenuated by the glucocorticoid receptor antagonist (RU-38,486) or by the glucocorticoid synthesis inhibitor (metyr- Nicotine (µg kg -1 , s.c.) Figure 4 Eects of combined treatment with RU-38,486 (30 mg kg 71 , s.c.), naloxone (two hourly injections of 1 mg kg 71 , i.p.) and ICI-118,551 (30 mg ml 71 , intra-articularly) on low-(a) and high-dose (b) nicotine inhibition of BK-induced plasma extravasation. (a) Combined treatment attenuated low-dose nicotine inhibition of BK-induced plasma extravasation (solid column, n=8) by an amount similar to that of naloxone alone (stippled column) (P40.05) but greater than that of control (without treatment) (open column, n=8), ICI-118,551 alone (hatched column, n=8), or RU-38,486 alone (cross-hatched column, n=8) (all P50.05). (b) Combined treatment attenuated high-dose nicotine inhibition of BK-induced plasma extravasation (solid column, n=8) by an amount signi®cantly greater than any of the antagonists alone (naloxone alone: stippled column, n=8; ICI-118,551 alone; hatched column, n=8; RU-38,486 alone: cross-hatched column, n=8) or the control (open column, n=8) (all P50.01). Dotted line represents changes of BK-induced plasma extravasation in rats that received nicotine-free vehicle injection over the same period of time as that after nicotine injection. *Signi®cantly dierent from the action produced by the same dose of nicotine in the controls (i.e., without treatment). Figure 5 Schematic diagram of proposed mechanism(s) underlying the inhibitory action of s.c., nicotine on synovial plasma extravasation. Nicotine is known to excite the adrenal medulla to release adrenaline (Cryer et al., 1976) and opioids (Wilson, 1991) ; and, via indirect actions, to release glucocorticoids (Krueger et al., 1991) . These adrenal hormones contribute to the decrease in plasma extravasation produced by nicotine. In addition, part of the eect of high-dose nicotine is mediated by spinal nicotinic mechanisms. apone). These observations support the notion that glucocorticoids also mediate the action of nicotine. While it was not possible to evaluate the intra-articular eect of RU-38,486 (i.e., its vehicle for administration is peanut oil), given its welldocumented ecacy when administered locally into in¯amed tissue, we suggest a local site of action of glucocorticoids in the joint.
The ®nding that the inhibitory action of a high-dose nicotine was attenuated by i.t. mecamylamine implicates the involvement of a spinal nicotinic mechanism. While the exact mechanism is not yet clear, possible mechanisms include a spinal ascending pathway (Miao et al., 1994 ) that projects to the hypothalamus and excites the hypothalamo-pituitary adrenal axis to release glucocorticoids and a spinal circuit which reduces regional blood¯ow by enhancing sympathetic out¯ow, that would non-selectively decrease plasma extravasation.
In an attempt to understand if these mechanisms of action (i.e., pathways mediated by adrenaline, opioids and glucocorticoids) are independent ones, we examined the eect of combined treatment by blocking receptors of these adrenal hormones on the magnitude of attenuated action of nicotine. We found that although the action of low-dose nicotine in the combined treatment group was not dierent from that produced by naloxone alone (note ICI-118,551 or RU-38,486 alone did not aect low-dose nicotine action), the action of high-dose nicotine in the combined treatment group was signi®cantly less than that produced by any of the single antagonists. Therefore, we believe that the neural and endocrine systems mediated, respectively, by adrenaline, opioids and glucocorticoids are, in fact, independent mechanisms. A schematic illustration of the proposed mechanisms is presented in Figure 5 .
In this study, nicotine, a selective agonist activating nicotinic cholinoceptors, was used as a tool to assess cholinergic control of neural and endocrine systems which may play a role in regulating microvascular permeability. An investigation into the role of nicotinic cholinergic circuitry in the regulation of the in¯ammatory response, including pain and vascular changes, will be important to the understanding of the physiological mechanisms which regulate the in¯ammatory process. Results from our study provide evidence to suggest that several adrenal hormones, which can be released by nicotine, mediate inhibition of synovial plasma extravasation.
